NICE guidance on AMD will not give advice on Avastin
This article was originally published in Scrip
Executive Summary
The National Institute for Health and Care Excellence (NICE) has begun consulting on a draft guideline on treatments for age-related macular degeneration covering all therapies that are currently being used for wet AMD, including Novartis's Lucentis (ranibizumab), Roche's Avastin (bevacizumab), and Bayer's Eylea (aflibercept).